Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Hims & Hers Health (HIMS)

Hims & Hers Q3 revenue rises 49% to $599.0 million; net income falls to $15.8 million

Mixed Impact 3 of 5 earnings Written later

Hims & Hers reported third quarter 2025 revenue of $599.0 million, up 49% from a year earlier, and Adjusted EBITDA of $78.4 million, up from $51.1 million. Net income fell to $15.8 million from $75.6 million, a year-earlier figure that included a $60.8 million tax benefit. The company narrowed its full-year 2025 revenue guidance to $2.335 billion to $2.355 billion and Adjusted EBITDA guidance to $307 million to $317 million.

Key points

  • Q3 2025 revenue was $599.0 million, up 49% from $401.6 million; subscribers reached 2,471 thousand, up 21%.
  • Q3 2025 net income was $15.8 million, compared with $75.6 million in Q3 2024, which included a $60.8 million tax benefit.
  • Q3 2025 Adjusted EBITDA was $78.4 million, up from $51.1 million; gross margin was 74%, down from 79%.
  • Full-year 2025 guidance was narrowed to $2.335 billion to $2.355 billion in revenue; Q4 2025 revenue guidance is $605 million to $625 million.

The filing

CompanyHims & Hers Health (HIMS)
Form8-K, current report
Filed with the SECNov 3, 2025, 4:08 PM ET
Accession number0001773751-25-000352

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.